Key result
DA-9701 did not improve total gastrointestinal symptom scores compared to placebo over 8 weeks in patients with postural orthostatic tachycardia syndrome.
Why the study?
Patients with postural orthostatic tachycardia syndrome commonly experience gastrointestinal symptoms, but no treatment has demonstrated clear efficacy in controlled trials.
Does DA-9701 improve gastrointestinal symptoms in patients with postural orthostatic tachycardia syndrome?
RCT (n=24)
Double-blind
1:1 block randomization
No
Does DA-9701 improve gastrointestinal symptoms in patients with postural orthostatic tachycardia syndrome?
In a pilot crossover trial of patients with POTS, DA-9701 did not significantly improve overall gastrointestinal symptoms, though it demonstrated a potential signal for improving specific symptoms like abdominal pain.
Answers are grounded in this paper and cite their sources.
Does not support DA-9701 for overall GI symptoms in POTS; leaves open targeted effects on specific symptoms for further trials.
Background/Aims: Patients with postural tachycardia syndrome (POTS) commonly experience gastrointestinal (GI) symptoms.We aim to assess the feasibility and preliminary efficacy data for DA-9701, a prokinetic agent targeting 5-hydroxytryptamine 1A, 5-hydroxytryptamine 4, and dopamine D 2 receptors, in patients with POTS.Methods: In a randomized, double-blind, placebo-controlled, single-center crossover trial, patients with POTS were given either 30 mg of DA-9701 or a placebo 3 times daily for eight weeks in a 1:1 ratio.After a 4-week washout, patients received the alternate treatment for another 8 weeks.The primary endpoint focused on assessing the change in GI symptoms (total Nepean Dyspepsia Index-Korean version [NDI-K] symptom score) from baseline over the 8 week-treatment period.Endpoints were assessed in all enrolled and randomized patients (intention-to-treat), and in those who completed the trial (per-protocol analysis).Results: Between January 2022 and August 2023, 24 patients were randomized (n = 12 per group), with 3 discontinuing after randomization.DA-9701 did not significantly improve primary endpoints for total NDI-K symptom scores in either the intention-to-treat (least-squares means, -13.9 vs. -9.5,P = 0.326) or per-protocol analyses (-17.2 vs -12.0,P = 0.242).Notably, a trend toward improvement in specific GI symptoms, such as upper abdominal pain, was observed in both intention-to-treat (-0.6 vs 0.7; P = 0.066) and per-protocol analyses (-0.9 vs 0.6; P = 0.045).No serious adverse events were observed.Conclusion: DA-9701 did not improve GI symptoms in this crossover trial; however, its potential effect on specific GI symptoms merits further investigation.
No takes yet. Share an insight, caveat, or question.
Jung et al. (2026) conducted an RCT in Postural Orthostatic Tachycardia Syndrome (POTS) with gastrointestinal symptoms (n=24). DA-9701 vs. Placebo was evaluated on Change in total Nepean Dyspepsia Index-Korean version (NDI-K) symptom score from baseline (MD -4.4, 95% CI -13.5 to 4.7, p=0.326). DA-9701 did not improve total gastrointestinal symptom scores compared to placebo over 8 weeks in patients with postural orthostatic tachycardia syndrome.
Synapse has enriched 10 related papers. Consider them for comparative context: